tirzepatide kidney function 🧬 New data from the SUMMIT trial reveals that long-term (Zepbound) may significantly improve in patients with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction ( Weight Loss Injections for Chronic

Stopping GLP-1 medications like semaglutide before surgery requires careful timing coordinated with your surgical team

Centers for Medicare and Medicaid Services

Carmot gets $150 million to finance its obesity pipeline

Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data.

Always great reporting and enjoyed contributing to this article from The New York Times and Dani Blum on the evolution of the GLP-1 market, specifically the growth of grey and illicit markets online